T. Chatellier

发表

Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab

J. Bennouna, E. Frampas, T. Goronflot, 2021, Cancer Immunology, Immunotherapy.

Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients

F. Joly, J. Malhaire, E. Voog, 2020, International journal of cancer.

Nivolumab‐induced celiac‐like enteropathy in patient with metastatic renal cell carcinoma: Case report and review of the literature

T. Matysiak-Budnik, C. Bossard, Y. Touchefeu, 2019, Clinical case reports.

Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort

C. Lepage, D. Spaeth, O. Bouché, 2022, Cancer medicine.

Multicenter Randomized Double-Blind, Placebo-Controlled Trial GORTEC (Groupe Oncologie Radiotherapie Tete et Cou) 2009-01 Evaluating the Effect of the Regenerating Agent on Radiodermatitis of Head and Neck Cancer Patients.

J. Bourhis, C. Sire, P. Blanchard, 2017, International journal of radiation oncology, biology, physics.

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial

J. Taïeb, S. Olschwang, V. Boige, 2022, Therapeutic advances in medical oncology.

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

P. Couzigou, M. Ducreux, C. Borel, 2018, European journal of cancer.

Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial.

J. Bourhis, C. Borel, P. Maingon, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

J. Mazières, R. Veillon, S. Hiret, 2023, Cancer Immunology, Immunotherapy.

Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics

A. Lièvre, C. Lepage, O. Bouché, 2016 .

Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial.

J. Bourhis, C. Borel, P. Maingon, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

J. Mazières, R. Veillon, S. Hiret, 2023, Cancer Immunology, Immunotherapy.

EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers

M. Tagliamento, L. Greillier, A. Toffart, 2024, NPJ precision oncology.